Revisiting T ype 2‐high and T ype 2‐low airway inflammation in asthma: current knowledge and therapeutic implications
D Robinson, M Humbert, R Buhl… - Clinical & …, 2017 - Wiley Online Library
Asthma is a complex respiratory disorder characterized by marked heterogeneity in
individual patient disease triggers and response to therapy. Several asthma phenotypes …
individual patient disease triggers and response to therapy. Several asthma phenotypes …
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind …
LG Heaney, J Busby, CE Hanratty… - The Lancet …, 2021 - thelancet.com
Background Asthma treatment guidelines recommend increasing corticosteroid dose to
control symptoms and reduce exacerbations. This approach is potentially flawed because …
control symptoms and reduce exacerbations. This approach is potentially flawed because …
FeNO in asthma
L Loewenthal, A Menzies-Gow - Seminars in respiratory and …, 2022 - thieme-connect.com
Asthma is a common disease affecting 350 million people worldwide, which is characterized
by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been …
by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been …
[HTML][HTML] Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma
ID Pavord, Y Deniz, J Corren, TB Casale… - The Journal of Allergy …, 2023 - Elsevier
BACKGROUND Fractional exhaled nitric oxide (FeNO) may have a role both as a prognostic
and predictive biomarker, in combination with eosinophils, for assessing responsiveness to …
and predictive biomarker, in combination with eosinophils, for assessing responsiveness to …
Pathogenesis of asthma: implications for precision medicine
RJ Russell, C Brightling - Clinical Science, 2017 - portlandpress.com
The pathogenesis of asthma is complex and multi-faceted. Asthma patients have a diverse
range of underlying dominant disease processes and pathways despite apparent similarities …
range of underlying dominant disease processes and pathways despite apparent similarities …
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in …
WW Busse, SE Wenzel, TB Casale… - The Lancet …, 2021 - thelancet.com
Background Fractional exhaled nitric oxide (FeNO) has potential as a prognostic biomarker
in asthma, but its prognostic value among other recognised indicators is unclear. We …
in asthma, but its prognostic value among other recognised indicators is unclear. We …
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group …
Background Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are
associated with important outcomes in mild asthma is unclear. In this prespecified subgroup …
associated with important outcomes in mild asthma is unclear. In this prespecified subgroup …
Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma
LG Heaney, J Busby, P Bradding… - American journal of …, 2019 - atsjournals.org
Rationale: Poor adherence is common in difficult-to-control asthma. Distinguishing patients
with difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory …
with difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory …